The immunization of mice with adjuvanted survivin peptide microparticles decreased the growth rate of primary tumors compared with control mice, suggesting that T-cell immunotherapy targeting survivin could be an applicable approach for the treatment of triple-negative breast cancer [53]. This evidence concerns the gene BIRC5 and triple-negative breast carcinoma.